Butenafine


Concise Prescribing Info
Indications/Uses
Skin fungal infections.
Dosage/Direction for Use
Adult : Topical As 1% cream: Tinea pedis: Apply bid for 7 days or once daily for 4 wk. Tinea corporis, tinea cruris: Apply once daily for 2 wk. Tinea versicolor: Apply once daily for 1-2 wk.
Dosage Details
Topical/Cutaneous
Skin fungal infections
Adult: As 1% cream: Tinea pedis: Apply to affected skin between and around the toes bid for 7 days or once daily for 4 wk. Tinea corporis and tinea cruris: Apply to affected area once daily for 2 wk. Tinea versicolor: Apply to affected area and surrounding skin once daily for 1-2 wk.
Child: ≥12 yr Same as adult dose.
Contraindications
Hypersensitivity to butenafine.
Special Precautions
Patients w/ allylamine antifungal (e.g. terbinafine, naftifine) hypersensitivity. Not intended for the treatment of scalp or nail infections.
Adverse Reactions
Burning/stinging sensation, contact dermatitis, erythema, pruritus, skin irritation.
Patient Counseling Information
Avoid contact w/ eyes or other mucous membranes. Avoid occlusive dressings.
MonitoringParameters
Perform direct microscopic examination of infected superficial epidermal tissue in potassium hydroxide (KOH) soln or culture examination using appropriate medium prior to initiation of treatment.
Action
Description: Butenafine, a benzylamine antifungal, inhibits the enzyme squalene monooxygenase, thus decreasing sterol biosynthesis w/ subsequent weakening of fungal cell membranes.
Pharmacokinetics:
Absorption: Minimal systemic absorption. Time to peak serum concentration: 6-15 hr.
Metabolism: Metabolised hepatically via hydroxylation.
Excretion: Elimination half-life: Biphasic: 35 hr; >150 hr.
Chemical Structure

Click on icon to see table/diagram/image
Storage
Store between 5-30°C.
ATC Classification
D01AE23 - butenafine ; Belongs to the class of other antifungals for topical use.
Disclaimer: This information is independently developed by MIMS based on Butenafine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in